Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments

1.3.1. List of players profiled in the report

1.4. Research Methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key Findings of the Study
2.2. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017
3.4. Porter's five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. High prevalence of biliary diseases
3.5.1.2. Technological advancements associated with biliary stents and urge in demand for minimally invasive procedures

3.5.2. Restraint

3.5.2.1. Complications and high costs associated with biliary stents

3.5.3. Opportunity

3.5.3.1. Development of innovative smartphone applications

Chapter: 4: U.S. BILIARY STENTS MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Metal Biliary Stents

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast

4.3. Plastic Biliary Stents

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast

Chapter: 5: U.S. BILIARY STENTS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Malignant obstruction

5.2.1. Market size and forecast

5.3. Benign biliary strictures

5.3.1. Market size and forecast

5.4. Biliary leaks

5.4.1. Market size and forecast

5.5. Others

5.5.1. Market size and forecast

Chapter: 6: U.S. BILIARY STENTS MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Market size and forecast

6.3. Ambulatory surgical centers

6.3.1. Market size and forecast

Chapter: 7: COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. B. BRAUN MELSUNGEN AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. BECTON, DICKINSON AND COMPANY

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. BOSTON SCIENTIFIC CORPORATION

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance

7.5. COOK MEDICAL INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio

7.6. CONMED CORPORATION

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Product portfolio

7.7. MEDTRONIC PLC

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance

7.8. MERIT MEDICAL SYSTEMS, INC.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. OLYMPUS CORPORATION

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance

7.10. TERUMO MEDICAL CORPORATION

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance